ArticleInternational journal of hematology2026

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

Yui Chikagawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.